Eli Lilly and Company (NYSE:LLY) Shares Bought by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 0.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,003 shares of the company’s stock after buying an additional 111 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Eli Lilly and Company were worth $14,183,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of LLY. XML Financial LLC boosted its holdings in Eli Lilly and Company by 1.0% in the 3rd quarter. XML Financial LLC now owns 1,775 shares of the company’s stock worth $1,572,000 after acquiring an additional 17 shares during the period. Sustainable Insight Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 5.9% in the third quarter. Sustainable Insight Capital Management LLC now owns 15,032 shares of the company’s stock valued at $13,317,000 after purchasing an additional 844 shares during the period. GSG Advisors LLC boosted its stake in shares of Eli Lilly and Company by 24.1% in the third quarter. GSG Advisors LLC now owns 412 shares of the company’s stock valued at $364,000 after purchasing an additional 80 shares during the period. Sheets Smith Wealth Management grew its holdings in Eli Lilly and Company by 48.6% during the 3rd quarter. Sheets Smith Wealth Management now owns 13,065 shares of the company’s stock valued at $11,574,000 after purchasing an additional 4,271 shares in the last quarter. Finally, First Personal Financial Services increased its stake in Eli Lilly and Company by 24.9% during the 3rd quarter. First Personal Financial Services now owns 301 shares of the company’s stock worth $267,000 after buying an additional 60 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 4.3 %

Shares of Eli Lilly and Company stock opened at $831.54 on Friday. The stock has a market capitalization of $789.40 billion, a price-to-earnings ratio of 89.90, a PEG ratio of 2.94 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The business’s 50 day simple moving average is $896.31 and its 200-day simple moving average is $867.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Eli Lilly and Company’s quarterly revenue was up 20.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.10 earnings per share. Equities research analysts forecast that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.63%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Morgan Stanley restated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Citigroup raised their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Bank of America cut their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.